Is it October already? Time to break out those scarves and mittens! As you’re digging through the attic this weekend, be sure to take a break to catch up on some recent headlines. From investigations into scientific integrity, to using crowdsourcing for drug development, you won’t want to miss the articles featured in this week’s Research Ethics Roundup.
New cures sought from old drugs: After Ionafarnib failed to effectively fight head and neck cancer—the disease it was originally designed to treat—researchers have found it to be successful at treating progeria, an unrelated illness. This success has inspired drug manufacturers to utilize crowdsourcing to search for alternative uses of failed drug compounds.
Seeking cures, patients enlist mice stand-ins: A new technique is allowing doctors to test the efficacy of several different drugs or doses simultaneously on a specific patient’s disease or immune system. The process involves transplanting the individual’s disease or immune system into several different mice, and then using the animals to test treatments before attempting them on the human subject.
Misconduct widespread in retracted science papers, study finds: A new study has found that in 2011—a year that saw an unprecedented rise in the number of retracted scientific papers—roughly three quarters of the retractions analyzed could be attributed to misconduct. According to one of the researchers, “the rising rate of retractions reflects perverse incentives that drive scientists to make sloppy mistakes or even knowingly publish false data.”
"Journalistic Deficit Disorder" is really very misleading in laying so much blame for slow turnover of data on mass news outlets. Even researchers who are directly trying to learn more based on previously published research will very often fail to turn up relevant contrary information even in other previously published research. Over time, prior research starts to look more and more definitive through citation networks. The Economist has mentioned this before.